Q2 EPS Estimate for Caribou Biosciences Increased by Analyst

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Equities researchers at HC Wainwright upped their Q2 2025 EPS estimates for Caribou Biosciences in a report issued on Monday, April 28th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.35) for the quarter, up from their prior estimate of ($0.47). HC Wainwright has a "Buy" rating and a $3.00 price target on the stock. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Caribou Biosciences' Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.43) EPS.

Separately, Bank of America reduced their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $9.33.

Caribou Biosciences Stock Performance

Shares of CRBU stock traded down $0.09 during trading hours on Thursday, hitting $0.77. The company had a trading volume of 448,052 shares, compared to its average volume of 1,546,934. The firm has a market capitalization of $71.61 million, a price-to-earnings ratio of -0.47 and a beta of 2.36. Caribou Biosciences has a 12 month low of $0.66 and a 12 month high of $3.93. The firm's fifty day moving average is $0.92 and its 200 day moving average is $1.49.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01. The firm had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

Institutional Trading of Caribou Biosciences

Institutional investors have recently made changes to their positions in the company. Centric Wealth Management purchased a new stake in Caribou Biosciences in the 4th quarter worth approximately $27,000. Cerity Partners LLC raised its stake in shares of Caribou Biosciences by 163.6% during the first quarter. Cerity Partners LLC now owns 40,722 shares of the company's stock valued at $37,000 after acquiring an additional 25,271 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Caribou Biosciences by 859.0% during the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock valued at $38,000 after acquiring an additional 21,416 shares in the last quarter. MetLife Investment Management LLC raised its stake in Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock worth $39,000 after buying an additional 9,148 shares in the last quarter. Finally, Diametric Capital LP purchased a new stake in Caribou Biosciences in the fourth quarter worth $42,000. Institutional investors own 77.51% of the company's stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.